Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677501 | 0.80 | APOBEC3G (0.57) | SLC6A4SLC6A2SLC6A3LMNAIFNAR1 | |
| Bipenamol SCHEMBL91233 | 0.78 | APOBEC3G (0.59) | SLC6A4SLC6A2SLC6A3PNMTPRMT3 | |
| Bipenamol SCHEMBL29444593 | 0.78 | APOBEC3G (0.59) | SLC6A4SLC6A2SLC6A3PNMTPRMT3 | |
| Bipenamol SCHEMBL636892 | 0.76 | APOBEC3G (0.57) | SLC6A4SLC6A2SLC6A3PNMTDPP4 | |
| Bipenamol SCHEMBL30791275 | 0.76 | APOBEC3G (0.57) | SLC6A4SLC6A2SLC6A3PNMTDPP4 | |
| SCHEMBL231454 | 0.75 | — | — | |
| SCHEMBL5333062 | 0.75 | CHRNA7 (0.53) | SLC6A4SLC6A2SLC6A3PNMTDPP4 | |
| SCHEMBL8530676 | 0.72 | MEN1 (0.52) | SLC6A4SLC6A2SLC6A3LMNATDP1 | |
| SCHEMBL29188822 | 0.72 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3PNMTPRMT3 | |
| SCHEMBL28879866 | 0.70 | PNMT (0.50) | SLC6A4SLC6A2SLC6A3PNMTPRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | SLC6A4 3251/4885SLC6A2 2019/4885SLC6A3 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.